Search company, investor...

Predict your next investment

Decheng Capital company logo
Venture Capital
decheng.com

Investments

94

Portfolio Exits

19

Funds

6

Service Providers

1

About Decheng Capital

Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with innovative technologies and growth-stage healthcare companies.

Headquarters Location

3000 Sand Hill Road Building 2, Suite 110

Menlo Park, California, 94025,

United States

650-233-0688

Want to inform investors similar to Decheng Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Decheng Capital News

Grit Biotechnology Closes $60M Series B Financing

Sep 8, 2023

Grit Biotechnology , a Shanghai, China-based cell therapy company, raised $60M in Series B funding. The round was led by CICC with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership and existing investors Sherpa Healthcare Partners, Decheng Capital and Matrix Partners China. The company intends to use the funds to support its Tumor-Infiltrating Lymphocyte (TIL) pipeline development, including the pivotal Phase II trial for GT101 and the advancement of gene-edited TIL products. Founded in 2019, Grit Biotechnology is a cell therapy company focused on delivering transformative cancer treatments. GT101 is currently the fastest-developing TIL therapy in China and will enter a Phase II trial by the end of 2023. The company has four core technology platforms central to its TIL development: StemTexp®, StaViral®, KOReTIL® and ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform. GT201, a genetically engineered TIL product by Grit Biotechnology, boosts T cell survival and function by expressing a vital membrane-bound cytokine. It surpasses traditional TIL therapies in proliferation, tumor-killing and persistence with reduced reliance on IL-2. GT201 IND is approved by CFDA and entered Phase I clinical trials. GT316, its TIL product, enhances TIL performance through knock-out of immunoregulatory targets identified via ImmuT Finder® CRISPR/Cas9 screening. In PDX mouse models, GT316 effectively eliminates tumors supported by low-dose IL-2 support with minimal toxicity. It offers substantial clinical benefits compared to conventional TIL products and is currently in IIT clinical trials in China. FinSMEs 08/09/2023

Decheng Capital Investments

94 Investments

Decheng Capital has made 94 investments. Their latest investment was in Cellares as part of their Series C on August 8, 2023.

CBI Logo

Decheng Capital Investments Activity

investments chart

Decheng Capital Portfolio Exits

19 Portfolio Exits

Decheng Capital has 19 portfolio exits. Their latest portfolio exit was Acelyrin on May 05, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/5/2023

IPO

$99M

Public

5

9/8/2022

Asset Sale

$99M

2

8/1/2022

Reverse Merger

$99M

3

9/24/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/18/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/5/2023

9/8/2022

8/1/2022

9/24/2021

8/18/2021

Exit

IPO

Asset Sale

Reverse Merger

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

5

2

3

10

10

Decheng Capital Fund History

6 Fund Histories

Decheng Capital has 6 funds, including Decheng Capital China Life Sciences USD Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2015

Decheng Capital China Life Sciences USD Fund II

Multi-Stage Venture Capital

Closed

2

6/6/2013

Decheng Capital China Life Sciences USD Fund I LP

Subscribe to see more

Subscribe to see more

$99M

10

Decheng Capital China Life Sciences RMB Fund I

Subscribe to see more

Subscribe to see more

10

Decheng Investment Fund

Subscribe to see more

Subscribe to see more

10

Decheng Capital Global Life Sciences Fund IV

10

Closing Date

12/31/2015

6/6/2013

Fund

Decheng Capital China Life Sciences USD Fund II

Decheng Capital China Life Sciences USD Fund I LP

Decheng Capital China Life Sciences RMB Fund I

Decheng Investment Fund

Decheng Capital Global Life Sciences Fund IV

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

Sources

2

10

10

10

10

Decheng Capital Service Providers

1 Service Provider

Decheng Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Decheng Capital Team

3 Team Members

Decheng Capital has 3 team members, including current Founder, Managing Director, Min Cui.

Name

Work History

Title

Status

Min Cui

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Min Cui

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Director

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.